Search

Postpartum infective endocarditis is a rare disease, especially in people with no risk factors (ie, intravenous drug use), that can be followed by severe morbidity and mortality. Here, we report a case of postpartum infective endocarditis with an unusual acute coronary syndrome-like presentation in a patient with minimal risk factors. In addition to lesions on the aortic valve causing severe aortic insufficiency, the patient’s case was also complicated by left main coronary artery embolization, which was subsequently aspirated during surgery. Repeat angiography demonstrated complete removal, with no evidence of downstream embolization. Résumé: L’endocardite infectieuse du post-partum est une maladie rare, en particulier en l’absence de facteur de risque (comme l’utilisation de drogues intraveineuses), qui peut être une cause de morbidité grave ou de mortalité. Nous décrivons ici un cas d’endocardite infectieuse du post-partum caractérisé par des symptômes inhabituels s’apparentant à un syndrome coronarien aigu, chez une patiente présentant peu de facteurs de risque. En plus de lésions de la valve aortique entraînant une insuffisance aortique grave, le cas de cette patiente a été compliqué par une embolie de l’artère coronaire gauche principale, traitée ultérieurement par aspiration au cours du traitement chirurgical. Une angiographie post-intervention a révélé la disparition complète des lésions sans signe d’embolie en aval.

Summary: The primary aim of the study is to investigate the temporal changes in plasma lipidome before and after reperfusion in patients with ST-segment elevation myocardial infarction (STEMI) and their association with myocardial injury. We found that 56% of the identified lipid species were significantly altered (corrected p< 0.05) in the first 24 h following reperfusion in patients with STEMI. Three lipid species, namely, acylcarnitine 18:2, TG 51:0, and LPC 17:1 were associated with a change in troponin concentration (delta troponin) and in-hospital cardiovascular events. Of these, acylcarnitine 18:2, and LPC 17:1 and their respective whole class levels, were significantly higher (p < 0.05) in the STEMI population than the age/sex-matched control subjects. Overall, our analyses showed a large shift in plasma lipidome in patients that undergo myocardial reperfusion. The differences found for acylcarnitines and LPC species and their association with both cardiac markers and cardiac outcomes need further validation.

The ‘no-reflow’ phenomenon (NRP) after primary percutaneous coronary intervention (PCI) is a serious complication among acute ST-segment elevation myocardial infarction (STEMI) patients. Herein, a comprehensive lipidomics approach was used to quantify over 300 distinct molecular species in circulating plasma from 126 patients with STEMI before and after primary PCI. Our analysis showed that three lipid classes: phosphatidylcholine (PC), alkylphosphatidylcholine (PC(O)), and sphingomyelin (SM), were significantly elevated (p < 0.05) in no-reflow patients before primary PCI. The levels of individual fatty acids and total fatty acid levels were significantly lower (p < 0.05) in no-reflow subjects after PCI. The grouping of patients based on ECG ST-segment resolution (STR) also demonstrated the same trend, confirming the possible role of these differential lipids in the setting of no-reflow. Sphingomyelin species, SM 41:1 and SM 41:2, was invariably positively correlated with corrected TIMI frame count (CTFC) at pre-PCI and post-PCI. The plasma levels of SM 42:1 exhibited an inverse association (p < 0.05) consistently with tumor necrosis factor-alpha (TNF-α) at pre-PCI and post-PCI. In conclusion, we identified plasma lipid profiles that distinguish individuals at risk of no-reflow and provided novel insights into how dyslipidemia may contribute to NRP after primary PCI.

Abstract Extreme coronary calcification may require rotational atherectomy to create a navigable intravascular lumen followed by intravascular lithotripsy to fracture areas of deep calcification to allow for successful percutaneous coronary intervention.

As an emerging platform technology, metabolomics offers new insights into the pathomechanisms associated with complex disease conditions, including cardiovascular diseases. It also facilitates assessing the risk of developing the disease before its clinical manifestation. For this reason, metabolomics is of growing interest for understanding the pathogenesis of acute coronary syndromes (ACS), finding new biomarkers of ACS, and its associated risk management. Metabolomics-based studies in ACS have already demonstrated immense potential for biomarker discovery and mechanistic insights by identifying metabolomic signatures (e.g., branched-chain amino acids, acylcarnitines, lysophosphatidylcholines) associated with disease progression. Herein, we discuss the various metabolomics approaches and the challenges involved in metabolic profiling, focusing on ACS. Special attention has been paid to the clinical studies of metabolomics and lipidomics in ACS, with an emphasis on ischemia/reperfusion injury.